Exelixis Inc (EXEL) Stock Price, Quote & News

Company Profile

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosin...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 837 7000

Fax: 650 837 8300

Website: www.exelixis.com

Address:

1851 Harbor Bay Parkway, Alameda, United States

inv1ncible Jan. 14 at 3:17 AM

$TGTX this stock reminds me of $EXEL . Stuck at same prices for years then boom $40’s

0 · Reply

ZacksResearch Jan. 12 at 7:30 PM

$EXEL misses revenue estimates for 2025 — what's next for the stock? 🤔 Despite strong sales of Cabometyx, preliminary revenues of $2.32B fell short of the Zacks Consensus Estimate of $2.33B. With a promising pipeline, including zanzalintinib, and plans to expand market presence, $EXEL is gearing for growth in 2026. Opportunity assessment here 👉 https://www.zacks.com/stock/news/2815675/exelixis-posts-preliminary-25-results-issues-26-outlook?cid=sm-stocktwits-2-2815675-body-28518&ADID=SYND_STOCKTWITS_TWEET_2_2815675_BODY_28518

1 · Reply

ZacksResearch Jan. 12 at 6:30 PM

$EXEL just put real numbers on the board — and the next phase is taking shape. 👀 EXEL posted approximately $2.32B in 2025 revenues and guided $2.525–$2.625B for 2026, driven by continued Cabometyx growth and an advancing zanzalintinib NDA. Full outlook and what’s driving the 2026 setup 👉 https://www.zacks.com/stock/news/2815675/exelixis-posts-preliminary-25-results-issues-26-outlook?cid=sm-stocktwits-2-2815675-teaser-28517&ADID=SYND_STOCKTWITS_TWEET_2_2815675_TEASER_28517

0 · Reply

OtherOtttawaGuy Jan. 12 at 12:25 AM

$EXEL Fiscal Year 2025 Fiscal Year 2026 Guidance Total revenues ~ $2.320 billion $2.525 billion - $2.625 billion Net product revenues ~ $2.123 billion $2.325 billion - $2.425 billion(1) Cost of goods sold, % of net product revenues ~ 3.7% 3.5% - 4.5% Research and development expenses ~ $825 million(2) $875 million - $925.X million(3) Selling, general and administrative expenses ~ $520 million(4) $575 million - $625 million(5) Effective tax rate n/a(6) 21% - 23% Ending cash and marketable securities(7) ~ $1.65 billion n/p

0 · Reply

OtherOtttawaGuy Jan. 12 at 12:25 AM

$EXEL 2025 Fidcal Year Results Cabozantinib franchise achieves approximately $2.123 billion in preliminary U.S. net product revenues for fiscal year 2025 – – Fiscal year 2026 net product revenues guidance of $2.325 billion - $2.425 billion – – Presentation and webcast at J.P. Morgan 2026 Healthcare Conference tomorrow, Monday, January 12th at 5:15 p.m. PT / 8:15 p.m. ET –

0 · Reply

DefenseMania Jan. 10 at 5:02 PM

$EXEL imo EXEL is very likely to be acquired this year , of course imo 😉

0 · Reply

Jblack500 Jan. 9 at 3:04 PM

$BBIO $INCY $MRK $EXEL $ABVX GILD MRK ABBV BMY CRDF ELAN the 11 names in my biotech basket (elan animal health)

0 · Reply

ZacksResearch Jan. 8 at 5:32 PM

Is $EXEL's zanzalintinib the next big thing in oncology? 🚀 With a promising phase III study expected to start in mid-2026 and a new drug application submitted for metastatic CRC, Exelixis is positioning zanzalintinib as a potential game-changer. Their collaboration with $NTRA could reshape MRD-guided therapies. Discover the full potential here 👉 https://www.zacks.com/stock/news/2814082/exel-collaborates-with-natera-for-late-stage-colorectal-cancer-study?cid=sm-stocktwits-2-2814082-body-28037&ADID=SYND_STOCKTWITS_TWEET_2_2814082_BODY_28037

0 · Reply

ZacksResearch Jan. 8 at 4:32 PM

$EXEL makes a late-stage move — and the stock is reacting 🧬 Exelixis teamed up with Natera on the phase III STELLAR-316 study, testing zanzalintinib in resected stage II/III colorectal cancer, and shares moved higher on the news. Get the full details on the collaboration here 👉 https://www.zacks.com/stock/news/2814082/exel-collaborates-with-natera-for-late-stage-colorectal-cancer-study?cid=sm-stocktwits-2-2814082-teaser-28035&ADID=SYND_STOCKTWITS_TWEET_2_2814082_TEASER_28035

0 · Reply

OtherOtttawaGuy Jan. 8 at 3:51 PM

$EXEL It just needs to break through that $46 level and stay above.

0 · Reply

Exelixis, Inc. (EXEL) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 11, 2026, 4:00 PM EST - 2 days ago

Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026

Jan 7, 2026, 8:00 AM EST - 6 days ago

Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer

NTRA

Jan 6, 2026, 4:05 PM EST - 7 days ago

Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026

Dec 31, 2025, 12:46 PM EST - 13 days ago

See How Rare Bullish Inflows Lift Outliers Like Exelixis

Dec 11, 2025, 6:12 AM EST - 4 weeks ago

Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D Day Transcript

Dec 3, 2025, 4:05 PM EST - 5 weeks ago

Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025

Nov 10, 2025, 1:41 PM EST - 2 months ago

Exelixis, Inc. (EXEL) Presents at Guggenheim Securities 2nd Annual Healthcare Innovation Conference Transcript

Nov 6, 2025, 9:39 PM EST - 2 months ago

Exelixis: The STELLAR Win Is A Mixed Bag, But Things Look Positive Still

Nov 6, 2025, 4:05 PM EST - 2 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November

Nov 4, 2025, 9:06 PM EST - 2 months ago

Exelixis, Inc. (EXEL) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:05 PM EST - 2 months ago

Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update

Oct 21, 2025, 4:05 PM EDT - 3 months ago

Exelixis to Release Third Quarter 2025 Financial Results on Tuesday, November 4, 2025

Oct 20, 2025, 10:48 AM EDT - 3 months ago

Exelixis Stock Falls After Phase 3 Colorectal Cancer Trial Shows Mixed Results

Oct 20, 2025, 2:30 AM EDT - 3 months ago

Exelixis Announces Detailed Results from Phase 3 STELLAR-303 Pivotal Trial Evaluating Zanzalintinib in Combination with an Immune Checkpoint Inhibitor in Metastatic Colorectal Cancer Presented at ESMO 2025 and Published in The Lancet

Oct 18, 2025, 3:00 AM EDT - 3 months ago

Exelixis Announces Results from Subgroup Analysis of CABINET Phase 3 Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Advanced Lung and Thymic Neuroendocrine Tumors at ESMO 2025

Sep 24, 2025, 12:33 PM EDT - 3 months ago

Exelixis, Inc. (EXEL) Presents at Bernstein 2nd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 10:20 AM EDT - 4 months ago

Exelixis, Inc. (EXEL) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 9, 2025, 1:06 PM EDT - 4 months ago

Exelixis, Inc. (EXEL) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 4, 2025, 10:06 AM EDT - 4 months ago

EXEL Investors Have Opportunity to Join Exelixis, Inc. Fraud Investigation with the Schall Law Firm

Sep 3, 2025, 7:43 PM EDT - 4 months ago

Exelixis, Inc. (EXEL) Presents At Citi's Biopharma Back To School Conference Transcript

Sep 3, 2025, 3:43 PM EDT - 4 months ago

Exelixis, Inc. (EXEL) Presents At 2025 Wells Fargo Healthcare Conference (Transcript)

Aug 29, 2025, 5:47 PM EDT - 4 months ago

Exelixis Announces Appointment of Dana T. Aftab, Ph.D.

Aug 27, 2025, 4:05 PM EDT - 4 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in September

Aug 25, 2025, 6:01 PM EDT - 5 months ago

Exelixis: RCC Stronghold, NET Launch, And A CRC Readout That Matters

Jul 31, 2025, 12:27 PM EDT - 5 months ago

Exelixis: Zanzalintinib Sees Mixed Progress, Cabozantinib Grinds Upwards

Jul 29, 2025, 12:32 PM EDT - 6 months ago

Analyst Surprised By Exelixis Q2 Revenue Miss, Delays STELLAR-304 Readout, Halts STELLAR-305 Phase 3 Plans

Jul 28, 2025, 10:51 PM EDT - 6 months ago

Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Jul 28, 2025, 4:05 PM EDT - 6 months ago

Exelixis Announces Second Quarter 2025 Financial Results and Provides Corporate Update

Jul 24, 2025, 5:04 PM EDT - 6 months ago

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

Jul 14, 2025, 4:05 PM EDT - 6 months ago

Exelixis to Release Second Quarter 2025 Financial Results on Monday, July 28, 2025

Jun 23, 2025, 12:58 PM EDT - 7 months ago

Exelixis: Zanzalintinib MOA Overcomes Competing CRC Regorafenib Treatment

Jun 23, 2025, 10:37 AM EDT - 7 months ago

Exelixis' Zanzalintinib Combo Boosts Survival In Colorectal Cancer, Stock Soars

Jun 22, 2025, 5:00 PM EDT - 7 months ago

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

Jun 20, 2025, 6:54 AM EDT - 7 months ago

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

May 23, 2025, 6:25 AM EDT - 8 months ago

Product Performance, Big Money Lift Exelixis

May 22, 2025, 5:17 PM EDT - 8 months ago

Exelixis Announces Encouraging Results from Phase 1b/2 STELLAR-002 Trial Evaluating Zanzalintinib in Combination with Immune Checkpoint Inhibitors in Advanced Kidney Cancer at ASCO 2025

May 22, 2025, 4:05 PM EDT - 8 months ago

Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May and June

May 14, 2025, 2:53 PM EDT - 8 months ago

Exelixis: A Notable Quarter

May 14, 2025, 10:44 AM EDT - 8 months ago

Exelixis Crushes Q1 Earnings Estimates With Strong Cabometyx Sales, Raises 2025 Revenue Guidance

May 13, 2025, 8:31 PM EDT - 8 months ago

Exelixis, Inc. (EXEL) Q1 2025 Earnings Call Transcript

May 13, 2025, 6:06 PM EDT - 8 months ago

Invenra Highlights Exelixis' Initiation of Phase 1 Clinical Study Evaluating XB628, a First-in-Class Bispecific Antibody in Participants with Recurrent Advanced or Metastatic Solid Tumors

May 13, 2025, 4:07 PM EDT - 8 months ago

Exelixis Announces First Quarter 2025 Financial Results and Provides Corporate Update

May 7, 2025, 4:05 PM EDT - 8 months ago

Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May

Apr 29, 2025, 4:05 PM EDT - 9 months ago

Exelixis to Release First Quarter 2025 Financial Results on Tuesday, May 13, 2025

Apr 29, 2025, 2:02 AM EDT - 9 months ago

EXEL Industries: Second quarter 2024–2025 sales down 3.8%

Mar 26, 2025, 9:15 AM EDT - 10 months ago

Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

inv1ncible Jan. 14 at 3:17 AM

$TGTX this stock reminds me of $EXEL . Stuck at same prices for years then boom $40’s

0 · Reply

ZacksResearch Jan. 12 at 7:30 PM

1 · Reply

ZacksResearch Jan. 12 at 6:30 PM

0 · Reply

OtherOtttawaGuy Jan. 12 at 12:25 AM

0 · Reply

OtherOtttawaGuy Jan. 12 at 12:25 AM

0 · Reply

DefenseMania Jan. 10 at 5:02 PM

$EXEL imo EXEL is very likely to be acquired this year , of course imo 😉

0 · Reply

Jblack500 Jan. 9 at 3:04 PM

$BBIO $INCY $MRK $EXEL $ABVX GILD MRK ABBV BMY CRDF ELAN the 11 names in my biotech basket (elan animal health)

0 · Reply

ZacksResearch Jan. 8 at 5:32 PM

0 · Reply

ZacksResearch Jan. 8 at 4:32 PM

0 · Reply

OtherOtttawaGuy Jan. 8 at 3:51 PM

$EXEL It just needs to break through that $46 level and stay above.

0 · Reply

AdamURAtoFookingNeptune Jan. 7 at 9:02 PM

$EXEL are we ready for beef

0 · Reply

Jblack500 Jan. 7 at 6:22 PM

@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $EXEL $ABVX $INCY

0 · Reply

cynicaloptimist Jan. 7 at 5:41 PM

@Jblack500 $EXEL 🤙

1 · Reply

topstockalerts Jan. 7 at 5:00 PM

Exelixis and Natera announced a collaboration on a pivotal Phase 3 trial in resected stage II/III colorectal cancer patients. The study, called STELLAR-316, will evaluate Exelixis’ oral kinase inhibitor zanzalintinib, with or without an immune checkpoint inhibitor, in patients identified as having molecular residual disease (MRD) using Natera’s Signatera test. The randomized trial targets a high-risk population with limited treatment options, as about 20% of stage II/III colorectal cancer patients remain MRD-positive after definitive therapy and face a high risk of recurrence. Disease-free survival will serve as the primary endpoint, with clearance of circulating tumor DNA as a key secondary endpoint. Exelixis expects to initiate the study in mid-2026, and success could position zanzalintinib as the first MRD-guided treatment in this setting. $EXEL $NTRA

0 · Reply

Invest2live Jan. 6 at 7:05 PM

$LCTX $SKYT $XERS $SKYT 145% already; congrats 🎈🌿🎈 Checkout $PHR and $EXEL; undervalued

0 · Reply

OtherOtttawaGuy Jan. 6 at 12:26 AM

$EXEL

0 · Reply

OtherOtttawaGuy Jan. 6 at 12:25 AM

$EXEL when from bearish to neutral on 4 posts?

0 · Reply

juice_rock Jan. 5 at 7:59 PM

$EXEL If BOA analysts are downgrading that's the Kiss of Future Gains. $50+ by February.

1 · Reply

AStrokeOfLuck Jan. 5 at 6:38 PM

$EXEL

0 · Reply

Jblack500 Jan. 3 at 2:40 AM

@WAJeff @cynicaloptimist @FannyPackin @Thelonius_Stonk @osubuckeye @Clargy @MaverikIT $ELAN $MRK $ABVX $EXEL $BBIO added to elan 22.10...cb a little over 18...I'll definitely add to it a few times if it comes back to the 18's...I see it as a hold of 12 months or more...they snuck in this fda approval on 12/31 https://finance.yahoo.com/news/elanco-receives-usda-approval-befrena-190000431.html

0 · Reply

StockBraker Dec. 31 at 3:05 PM

$EXEL Buying at $40 if it gets there.

0 · Reply

Tangle22 Dec. 30 at 9:31 PM

$EXEL why - year end

0 · Reply

Market Cap	11.81B
Revenue (ttm)	2.17B
Net Income (ttm)	521.27M
EPS (ttm)	N/A
PE Ratio	18.90
Forward PE	15.89
Profit Margin	24.04%
Debt to Equity Ratio	0.00

Volume	2,082,400
Avg Vol	2,691,328
Day's Range	N/A - N/A
Shares Out	268.11M
Stochastic %K	49%
Beta	0.40
Analysts	Sell
Price Target	$46.00